Age-related Eye Disease Study 2: perspectives, recommendations, and unanswered questions
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
PURPOSE OF REVIEW: This review provides a perspective on the Age-related Eye Disease Study 2 (AREDS2) including a summary of the goals and rationale of the study, major findings, subsequent management recommendations, and questions that remain to be answered. RECENT FINDINGS: The primary goal of the AREDS2 was to evaluate the efficacy and safety of lutein plus zeaxanthin and/or omega-3 long-chain polyunsaturated acid supplementation in reducing the risk of developing advanced age-related macular degeneration (AMD). AREDS2 also investigated the effects of omitting β-carotene and reducing the concentration of zinc from the original AREDS formulation. Although primary analysis from the AREDS2 did not reveal a benefit of daily supplementation with lutein/zeaxanthin on AMD progression, secondary exploratory analyses suggested that lutein/zeaxanthin were helpful in reducing this risk. Comparison of low-dose to higher-dose zinc showed no significant benefit. SUMMARY: The overall evidence on the beneficial and adverse effects from AREDS2 and other studies suggests that lutein/zeaxanthin could be more appropriate than β-carotene in AREDS-type supplements. Questions remain regarding the AREDS2 study results such as: whether the findings are generalizable to the population as a whole, what is the long-term safety profile of lutein/zeaxanthin supplementation, should other carotenoids be included in AREDS-type supplements, and at what optimal doses?
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522 · cited 11×
“Lower zinc dose and elimination of b-carotene Lowering zinc dose (from 80 to 25 mg) and eliminating b-carotene had no statistically significant effect on progression to advanced AMD.”
InfluentialCauses and Prevalence of Visual Impairment Among Adults in the UnitedStates
(2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.4.477 · Cited by 2,616
Omenn, G. S., Goodman, G. E., Thornquist, M. D., Balmes, J., Cullen, M. R., Glass, A., Keogh, J. P., Meyskens, F. L., Valanis, B., Williams, J. H., et al. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.21.1550 · Cited by 1,255 · cited 1×
“carotene was secondary to reports that suggested an increased risk for developing lung cancer in cigarette smokers taking supplements containing b-carotene [23,24].”
Chew, E. Y., Clemons, T. E., SanGiovanni, J. P., Danis, R. P., Ferris, F. L., Elman, M. J., Antoszyk, A. N., Ruby, A. J., Orth, D., Bressler, S. B., et al. (2014) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2013.7376 · Cited by 415
Self-citationDietary Antioxidants and the Long-term Incidence of Age-Related Macular Degeneration
Tan, J. S. L., Wang, J. J., Flood, V., Rochtchina, E., Smith, W., & Mitchell, P. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2007.03.083 · Cited by 381
Albanes, D., Heinonen, O., Huttunen, J., Taylor, P., Virtamo, J., Edwards, B., Haapakoski, J., Rautalahti, M., Hartman, A., & Palmgren, J. (1995) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/62.6.1427s · Cited by 379
Oral Zinc in Macular Degeneration
Newsome, D. A., Swartz, M., Leone, N. C., Elston, R. C., & Miller, E. (1988) · Archives of Ophthalmology · doi:10.1001/archopht.1988.01060130202026 · Cited by 349 · cited 1×
“The reasoning behind lowering zinc levels was that although a dose of 80 mg was used in the original AREDS formulation based on a prior trial suggesting efficacy, there was also evidence to suggest that the maximal level absorbed was closer to 25 mg [25,26].”
SanGiovanni, J. P., Agrón, E., Meleth, A. D., Reed, G. F., Sperduto, R. D., Clemons, T. E., & Chew, E. Y. (2009) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2009.27594 · Cited by 186
Self-citation
Cited by
Industrial potential of carotenoid pigments from microalgae: Current trends and future prospects
Ambati, R. R., Gogisetty, D., Aswathanarayana, R. G., Ravi, S., Bikkina, P. N., Bo, L., & Yuepeng, S. (2019) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2018.1432561 · Cited by 372
Overview of carotenoid bioavailability determinants: From dietary factors to host genetic variations
Desmarchelier, C., & Borel, P. (2017) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2017.03.002 · Cited by 276
Kalra, R., Gaur, S., & Goel, M. (2021) · Journal of Water Process Engineering · doi:10.1016/j.jwpe.2020.101794 · Cited by 140
Mechanisms of Transport and Delivery of Vitamin A and Carotenoids to the Retinal Pigment Epithelium
Harrison, E. H. (2019) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201801046 · Cited by 97
RPE65 takes on another role in the vertebrate retina
Redmond, T. M. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1715064114 · Cited by 7
Metadata
- Authors
- Aronow, M. E., & Chew, E. Y.
- Venue
- Current Opinion in Ophthalmology
- Published
- 2014-05
- Volume
- 25
- Issue
- 3
- Pages
- 186-190
- ISSN
- 1040-8738 (ISSN-L)
- OpenAlex
- W1994887552
- Cited by
- 70
- References
- 10
- FWCI
- 7.70
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Age-related Eye Disease Study 2: perspectives, recommendations, and unanswered questions. https://app.cochat.ai/papers/10.1097/icu.0000000000000046
- The paper
- Aronow, M. E., & Chew, E. Y. (2014). Age-related Eye Disease Study 2: perspectives, recommendations, and unanswered questions. Current Opinion in Ophthalmology. https://doi.org/10.1097/icu.0000000000000046
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.